{
    "clinical_study": {
        "@rank": "75794", 
        "arm_group": {
            "arm_group_label": "Treatment (tipifarnib)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive tipifarnib PO BID on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best dose of tipifarnib in treating patients\n      with myelodysplastic syndromes. Tipifarnib may stop the growth of cancer cells by blocking\n      some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Tipifarnib in Treating Patients With Myelodysplastic Syndromes", 
        "condition": [
            "Chronic Myelomonocytic Leukemia", 
            "de Novo Myelodysplastic Syndromes", 
            "Previously Treated Myelodysplastic Syndromes", 
            "Refractory Anemia", 
            "Refractory Anemia With Excess Blasts", 
            "Refractory Anemia With Excess Blasts in Transformation", 
            "Refractory Anemia With Ringed Sideroblasts", 
            "Refractory Cytopenia With Multilineage Dysplasia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Refractory", 
                "Anemia, Refractory, with Excess of Blasts", 
                "Leukemia", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Acute", 
                "Anemia, Aplastic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the toxicity profile and antitumor activity of the farnesyltransferase\n      (FTase) inhibitor R115777 (tipifarnib) in patients with myelodysplastic syndrome (MDS)\n      treated on a one week on/one week off schedule.\n\n      II. To determine the effect on R115777 on a one week on/one week off schedule on FTase\n      activity, prenylation of RAS and other substrates and on downstream effects.\n\n      OUTLINE: This is a dose-escalation study.\n\n      Patients receive tipifarnib orally (PO) twice daily (BID) on weeks 1, 3, 5, and 7. Treatment\n      repeats every 8 weeks for up to 2 courses in the absence of disease progression or\n      unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically MDS (including French-American-British [FAB] types\n             refractory anemia [RA], refractory anemia with ringed sideroblasts [RARS], refractory\n             anemia with excess blasts [RAEB], refractory anemia with excess blasts in\n             transformation [RAEBT], or chronic myelomonocytic leukemia [CMMoL]); for the purpose\n             of the study, all patients will be classified by World Health Organization (WHO)\n             criteria\n\n               -  By these criteria, FAB RA are split into:\n\n               -  Pure dyserythropoietic refractory anemia (PRA)\n\n                    -  Refractory cytopenia with multilineage dysplasia (RCMD)\n\n               -  FAB RARS is split into:\n\n                    -  Pure sideroblastic anemia (PSA)\n\n                    -  Refractory sideroblastic cytopenia with multilineage dysplasia (RSCMD)\n\n               -  FAB RAEB is split into:\n\n                    -  RAEB I (< 10% BM blasts)\n\n                    -  RAEB II (10-20% BM blasts)\n\n               -  Patients with CMMoL, and RAEBT by FAB classification will be included in the\n                  protocol\n\n          -  Prognosis will be assessed by International Prognostic Scoring System (IPSS) criteria\n\n          -  =< 2 prior therapies\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n\n          -  Life expectancy of greater than 12 weeks\n\n          -  Bilirubin =< 1.5mg %\n\n          -  Creatinine =< 1.5mg %\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control) prior to study entry and for the\n             duration of study participation; should a woman become pregnant or suspect she is\n             pregnant while participating in this study, she should inform her treating physician\n             immediately\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (3 months for\n             UCN01) prior to entering the study or those who have not recovered from adverse\n             events due to agents administered more than 4 weeks earlier\n\n          -  Patients may not be receiving any other investigational agents\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to R115777 (such as imidazoles)\n\n          -  Patients eligible for bone marrow transplant (=< 60 years old), with a compatible\n             sibling, no contraindications for transplant\n\n          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n             the mother is treated with R115777.\n\n          -  Growth factors other than filgrastim (G-CSF) are excluded; patients should be off\n             excluded growth factors for 2 weeks"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005845", 
            "org_study_id": "NCI-2009-01158", 
            "secondary_id": [
                "NCI-2009-01158", 
                "CDR0000067862", 
                "DM01-582", 
                "5625", 
                "U01CA062461"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (tipifarnib)", 
                "description": "Given PO", 
                "intervention_name": "tipifarnib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "R115777", 
                    "Zarnestra"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tipifarnib)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (tipifarnib)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tipifarnib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "M D Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of the Farnesyl Transferase Inhibitor R115777 (NSC #702818) in Patients With Myelodysplastic Syndrome", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Razelle Kurzrock", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The final analysis will report all toxicities by grade, dose, cycle, and by cumulative dose.", 
                "measure": "MTD defined as the next lower dose level at which 2 patients experience dose limiting toxicity (DLT) defined as grade 3 or 4 toxicity according to the Cancer Therapy Evaluation Program Common Toxicity Criteria", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8.5 years"
            }, 
            {
                "description": "Will be reported overall and by dose level.", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 8.5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005845"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Based on the shape of the relationship (e.g. linear vs saturation vs peak), a dose response analysis will be performed to describe/summarize the relationship (correlation analysis or curve-fitting).", 
                "measure": "FTase inhibition", 
                "safety_issue": "No", 
                "time_frame": "Up to 8.5 years"
            }, 
            {
                "description": "Based on the shape of the relationship (e.g. linear vs saturation vs peak), a dose response analysis will be performed to describe/summarize the relationship (correlation analysis or curve-fitting).", 
                "measure": "Accumulation of unfarnesylated lamin B1", 
                "safety_issue": "No", 
                "time_frame": "Up to 8.5 years"
            }, 
            {
                "description": "Based on the shape of the relationship (e.g. linear vs saturation vs peak), a dose response analysis will be performed to describe/summarize the relationship (correlation analysis or curve-fitting).", 
                "measure": "Accumulation of RAS proteins", 
                "safety_issue": "No", 
                "time_frame": "Up to 8.5 years"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }, 
    "geocoordinates": {
        "M D Anderson Cancer Center": "29.76 -95.369"
    }
}